U.S. markets closed

Silk Road Medical, Inc (SILK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
60.11-1.78 (-2.88%)
At close: 4:00PM EDT

60.11 0.00 (0.00%)
After hours: 4:24PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close61.89
Open60.99
Bid56.50 x 800
Ask60.05 x 800
Day's Range59.42 - 61.46
52 Week Range20.84 - 72.19
Volume179,522
Avg. Volume329,779
Market Cap2.024B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Silk Road Medical to Report Third Quarter 2020 Financial Results on November 10, 2020
    GlobeNewswire

    Silk Road Medical to Report Third Quarter 2020 Financial Results on November 10, 2020

    SUNNYVALE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3146919. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.    About Silk Road Medical Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.Investor Contact: Lynn Lewis or Caroline Paul Gilmartin Group investors@silkroadmed.com

  • Hedge Funds Dipping Their Toes Into Silk Road Medical, Inc. (SILK)
    Insider Monkey

    Hedge Funds Dipping Their Toes Into Silk Road Medical, Inc. (SILK)

    The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]

  • GlobeNewswire

    Silk Road Medical Names Rick Anderson to Board of Directors

    SUNNYVALE, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that medical device industry veteran Rick Anderson has joined its board of directors. Anderson brings over 30 years of senior executive leadership experience in the medical device industry. He is the Chairman and Managing Director of Revival Healthcare Capital, a sustainable, high impact investment firm that specializes in medical devices and diagnostics. He currently serves on the boards of Apollo Endosurgery (Nasdaq: APEN) and Cardiologs, a leading cardiovascular artificial intelligence company; on the Executive Advisory Board of LEK Consulting, a leading healthcare consulting firm; and as an Independent Director of ConvaTec Group Plc, a FTSE 250 company specializing in medical products and related technologies. Anderson previously served as Chairman of the Board and CEO of ConvaTec Group Plc, where in his one-year interim roles he created additional shareholder value through his “Pivot to Growth” strategy and new $150 million transformation plan. He also previously served as Chairman of the Board for Cardiva Medical, IDEV Technologies, and Tryton Medical, and served as Director on the boards of Intersect ENT and multiple other medical device companies.Prior to founding Revival, Anderson served as a Managing Director at PTV Healthcare Capital, a venture capital and private equity firm specializing in the healthcare and life science industries. He also served as the Company Group Chairman of Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Anderson was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER® Sirolimus-eluting Coronary Stent. Anderson holds a B.B.A. in Marketing from Mississippi State University.“Rick is an acclaimed leader in the medical device industry with notable experience as a board member working to drive growth,” said Erica Rogers, Chief Executive Officer. “I look forward to his insight and guidance as we continue to advance TCAR’s role in preventing stroke.”“Silk Road Medical has revolutionized the treatment of carotid artery disease and I am honored to be joining the Board of Directors,” said Anderson. “I am excited to be working with this wonderful team to continue to expand their tremendous market opportunities.”About Silk Road Medical Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.About Revival Healthcare Capital Revival Healthcare Capital is a sustainable, high impact investment platform specializing in the medical device and diagnostic sectors of healthcare. To learn more, visit rvlhc.com.Investors: Lynn Lewis or Caroline Paul Gilmartin Group investors@silkroadmed.comMedia: Michael Fanucchi Silk Road Medical mfanucchi@silkroadmed.com